NCT03011034 · Interventional trial
Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Overall registry status Completed
Phase 2
Conditions Myelodysplastic Syndromes
Delaware Valley sites
- University of Pennsylvania Abramson Cancer Center · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory